Why the study?
Does oral quinidine bisulphate suppress electrical storm and ventricular fibrillation recurrence in an adolescent with malignant Brugada syndrome?
Does oral quinidine bisulphate suppress electrical storm and ventricular fibrillation recurrence in an adolescent with malignant Brugada syndrome?
Oral quinidine bisulphate may be an effective adjunctive therapy for suppressing electrical storm in patients with malignant Brugada syndrome.
May support quinidine in refractory adolescent Brugada storm; hypothesis-generating and requires prospective validation before practice change.
We report an adolescent with a malignant form of Brugada syndrome who presented with 15 episodes of ventricular fibrillation (VF) over 10 days, shortly after implantation of an implantable cardioverter defibrillator. Oral quinidine bisulphate at a dose of 1000 mg/day successfully suppressed the electrical storm and recurrence of VF over 18-month follow-up. It also normalized the ST-segment elevation in his right precordial leads, suppressed all ambient unifocal ventricular extrasystoles and induction of VF on programmed electrical stimulation. This case suggests that quinidine, by virtue of its blocking action on Ito, may be useful as adjunctive therapy in Brugada syndrome.
No takes yet. Share an insight, caveat, or question.
Mok et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: